Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the Data and Safety Monitoring Board (“DSMB”) completed its sixth assessment of the EffiKIR study and...

Cash, cash equivalents and financial instruments amounting to €274 million*; Landmark co-development and commercialization agreement with AstraZeneca for monalizumab in immuno-oncology; Building...

Multicenter, open-label, dose-escalation and cohort-expansion Phase I study of durvalumab in combination with monalizumab in patients with solid tumors; Trial performed by AstraZeneca/MedImmune in the...

Research collaboration and licensing agreement for new bispecific antibodies using Innate Pharma’s technology and Sanofi’s technology and tumor targets Innate Pharma eligible for up to €400m in...

This program, currently in preclinical development, aims at developing an anti-CD39 mAb; Targeting the adenosine immunosuppressive pathway has potential to promote anti-tumor immune responses across a...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its tentative financial calendar for 2016, which is set as follows: February 18, 2016 : Publication of 2015...

Phase Ib/II trial testing monalizumab in combination with cetuximab in patients with relapsed or refractory head and neck cancer Trial conducted in Europe and the United States Innate Pharma SA (the...

Proprietary, new cytotoxic anti-KIR3DL2 monoclonal antibody in development for the treatment of cutaneous T-cell lymphoma (CTCL); Orphan drug designation in the European Union; Innate’s third first-in...

8 trials ongoing with lirilumab in multiple indications and combinations 5 combination trials ongoing in hemato-oncology Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) announced...